First-line therapy with temozolomide induces regression of primary CNS lymphoma

Neurology

Volumn 58, Issue 10, 2002, Pages 1573-1574

  Herrlinger, Ulrich ^a   Kuker W ^a   Platten, M ^a   Dichgans, J ^a   Weller, M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; LOMUSTINE; METHOTREXATE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOCOMPETENCE; MALE; NEUROPATHOLOGY; NEUROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037188372     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.10.1573     Document Type: Article

References (7)

1. Long-term survival in primary CNS lymphoma
2. Primary CNS lymphoma 1991-1997: Outcome and late adverse effects after combined modality treatment
3. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma. Response to therapy and quality of life of patients
4. NOA-03 multi-center trial of single agent high-dose methotrexate for primary CNS lymphoma
5. PCV salvage chemotherapy for primary CNS lymphoma
6. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma
7. Combined treatment with high dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients